NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free CLRB Stock Alerts $2.50 +0.17 (+7.30%) (As of 06/28/2024 ET) Add Compare Share Share Today's Range$2.34▼$2.5550-Day Range$2.33▼$3.4252-Week Range$1.56▼$4.45Volume913,440 shsAverage Volume504,971 shsMarket Capitalization$89.62 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cellectar Biosciences alerts: Email Address Cellectar Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside700.0% Upside$20.00 Price TargetShort InterestBearish6.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.51) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector765th out of 916 stocksPharmaceutical Preparations Industry353rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectar Biosciences has received no research coverage in the past 90 days.Read more about Cellectar Biosciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.83% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently increased by 9.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLRB. Previous Next 1.8 News and Social Media Coverage News SentimentCellectar Biosciences has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cellectar Biosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions.Read more about Cellectar Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.51) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cellectar Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Cellectar Biosciences Stock (NASDAQ:CLRB)Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More CLRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLRB Stock News HeadlinesJune 27 at 6:40 AM | globenewswire.comCellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market LandscapeMay 29, 2024 | globenewswire.comCellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis FungoidesJune 30, 2024 | Darwin (Ad)Discover AI Giants?Wondering which AI stocks are set to soar in 2024? We’ve identified the top 3, and we're excited to share them with you! Unlock immediate access to our exclusive report and discover... the key players and strategic insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 24, 2024 | msn.comCellectar Biosciences files for $300M mixed securities shelfMay 22, 2024 | finance.yahoo.comIs Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?May 20, 2024 | seekingalpha.comCellectar Biosciences: Still Working On That Hit (Maintain Buy)May 16, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug PipelineMay 15, 2024 | msn.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call TranscriptJune 30, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 15, 2024 | finance.yahoo.comCellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Cellectar Biosciences Inc Earnings CallMay 14, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024May 14, 2024 | markets.businessinsider.comCellectar Biosciences Inc Loss At -$21.58 Mln In Q1May 14, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate UpdateMay 8, 2024 | globenewswire.comCellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 7, 2024 | globenewswire.comCellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024May 2, 2024 | morningstar.comCellectar Biosciences Inc CLRBApril 19, 2024 | seekingalpha.comCLRB Cellectar Biosciences, Inc.March 29, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid FinancialsMarch 29, 2024 | nz.finance.yahoo.comJeremy Renner Sweetly Hugs Daughter Ava in Rare Photo as He Celebrates His 'Number One' on Her 11th BirthdayMarch 29, 2024 | finance.yahoo.comCellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?March 28, 2024 | finance.yahoo.comQ4 2023 Cellectar Biosciences Inc Earnings CallMarch 27, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023March 27, 2024 | msn.comCellectar Biosciences FY 2023 Earnings PreviewMarch 27, 2024 | benzinga.comEarnings Preview For Cellectar BiosciencesMarch 27, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate UpdateMarch 20, 2024 | globenewswire.comCellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024See More Headlines Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/30/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLRB CUSIPN/A CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+700.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,821.29% Return on Assets-200.45% Debt Debt-to-Equity RatioN/A Current Ratio2.54 Quick Ratio2.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-6.94Miscellaneous Outstanding Shares35,850,000Free Float34,523,000Market Cap$89.63 million OptionableOptionable Beta1.00 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. James V. Caruso (Age 65)President, CEO & Director Comp: $1.14MMr. Chad J. Kolean CPA (Age 60)VP, CFO & Secretary Comp: $711.23kMr. Jarrod Longcor (Age 51)Chief Operating Officer Comp: $854.24kMr. Darrell Shane Lea (Age 50)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 52)Senior Vice President of Medical Key CompetitorsUroGen PharmaNASDAQ:URGNAcelyrinNASDAQ:SLRNFulcrum TherapeuticsNASDAQ:FULCEmergent BioSolutionsNYSE:EBSErascaNASDAQ:ERASView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 708,191 shares on 5/10/2024Ownership: 3.322%Rosalind Advisors Inc.Sold 1,384,180 shares on 4/25/2024Ownership: 1.926%View All Institutional Transactions CLRB Stock Analysis - Frequently Asked Questions Should I buy or sell Cellectar Biosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLRB shares. View CLRB analyst ratings or view top-rated stocks. What is Cellectar Biosciences' stock price target for 2024? 2 Wall Street research analysts have issued 1 year price objectives for Cellectar Biosciences' stock. Their CLRB share price targets range from $12.00 to $28.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 700.0% from the stock's current price. View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts. How have CLRB shares performed in 2024? Cellectar Biosciences' stock was trading at $2.77 at the beginning of 2024. Since then, CLRB stock has decreased by 9.7% and is now trading at $2.50. View the best growth stocks for 2024 here. Are investors shorting Cellectar Biosciences? Cellectar Biosciences saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,370,000 shares, an increase of 9.2% from the May 31st total of 2,170,000 shares. Based on an average trading volume of 684,700 shares, the short-interest ratio is currently 3.5 days. Approximately 6.8% of the shares of the company are sold short. View Cellectar Biosciences' Short Interest. When is Cellectar Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CLRB earnings forecast. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. When did Cellectar Biosciences' stock split? Cellectar Biosciences shares reverse split before market open on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM). How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLRB) was last updated on 6/30/2024 by MarketBeat.com Staff From Our PartnersElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | SponsoredYour bank account could be compromisedLegendary financial forecaster, Dr. Martin Weiss has recently uncovered the government's chilling new program ...Weiss Ratings | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredA new pathway to wealth was born inside my wine-cellarThese days, the “right” to receive a welfare check enjoys greater popularity than the right to make a living. ...Porter & Company | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.